Five-year cervical (pre)cancer risk of women screened by HPV and cytology testing

Cancer Prevention Research

Volumn 8, Issue 6, 2015, Pages 502-508

  Uijterwaal, Margot H ^a   Polman, Nicole J ^a   Van Kemenade, Folkert J ^b   Van Den Haselkamp, Sander ^a   Witte, Birgit I ^c   Rijkaart, Dorien ^a   Berkhof, Johannes ^c   Snijders, Peter J F ^a   Meijer, Chris J L M ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS VIRUS TEST; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SERODIAGNOSIS; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERUS CARCINOMA; WART VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; COMPARATIVE STUDY; CYTODIAGNOSIS; EARLY CANCER DIAGNOSIS; FOLLOW UP; MIDDLE AGED; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOGENICITY; PROGNOSIS; TIME FACTOR; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CYTODIAGNOSIS; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84941797144     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0409     Document Type: Article

References (35)

1. Arbyn M, Ronco G, Anttila A, Meijer CJLM, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testinginsecondary prevention of cervical cancer. Vaccine 2012;30 Suppl 5:F88-F99.
2. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524-32.
3. Rijkaart DC, Berkhof J, van Kemenade FJ, Rozendaal L, Verheijen RHM, Bulk S, etal. Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population-based cervical screening (VUSA-screen study). Int J Cancer 2010;126:2175-81.
4. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VMH, Rozendaal L, Heideman DAM, et al. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer 2012;106:975-81.
5. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VMH, Hesselink AT, Rozendaal L, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012;130:602-10.
6. Hopman EH, Rozendaal L, Voorhorst FJ, Walboomers JM, Kenemans P, Helmerhorst TJ. High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. BJOG 2000;107:600-4.
7. Luesley D, Leeson S. Colposcopy and programme management: guidelines for the NHS cervical screening programme 2010, NHSCSP 20 (2nd ed.). Sheffield, United Kingdom: NHS Cancer Screening Programmes.
8. Wright TC, Kurman RJ, Ferenczy A. Precancerous lesions of the cervix. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract. 5th ed. New York: Springer Verlag; 2002. p. 253-93.
9. Bulk S, van Kemenade FJ, Rozendaal L, Meijer CJ. The Dutch CISOE-a framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004;57:388-93.
10. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
11. van den Brule AJC, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJLM, Snijders PJF. GP5+/6 +PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002;40:779-87.
12. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44, 102 women. Int J Cancer 2004;110:94-101.
13. Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de PA, van Krieken JH, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 2007;29:19-24.
14. R Development Core team. R: a language and environment for statistical Computing. Vienna, Austria: R Foundation for Statistical Computing (http://www. R-project.org/).
15. Dijkstra MG, van Niekerk D, Rijkaart DC, van Kemenade FJ, Heideman DAM, Snijders PJF, et al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiol Biomarkers Prev 2014;23:55-63.
16. Wright TCJ, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81-6.
17. Gezondheidsraad. Screening op baarmoederhalskanker. Den Haag: Gezondheidsraad; 2011.
18. Wright TCJ, Stoler MH, Sharma A, Zhang G, Behrens C, Wright TL. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPVp cytology-negative results. Am J Clin Pathol 2011;136:578-86.
19. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-9.
20. Gok M, Heideman DAM, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JWM, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 2010;340:c1040.
21. Gok M, van Kemenade FJ, Heideman DAM, Berkhof J, Rozendaal L, Spruyt JWM, et al. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program. Int J Cancer 2012;130:1128-35.
22. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, etal. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:249-57.
23. Bulkmans NWJ, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJP, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-72.
24. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NWJ, Heideman DAM, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012;13:78-88.
25. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12:663-72.
26. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, etal. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
27. Cuzick J, Szarewski A, Mesher D, Cadman L, Austin J, Perryman K, et al. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-results from the Hammersmith study. Int J Cancer 2008;122:2294-300.
28. Mesher D, Szarewski A, Cadman L, Cubie H, Kitchener H, Luesley D, et al. Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. Br J Cancer 2010;102:1405-10.
29. Elfstrom KM, Smelov V, Johansson ALV, Eklund C, Naucler P, Arnheim-Dahlstrom L, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ 2014;348:g130.
30. Castle PE, Glass AG, Rush BB, Scott DR, Wentzensen N, Gage JC, et al. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol 2012;30:3044-50.
31. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008;111:167-77.
32. Siebers AG, Klinkhamer PJJM, Arbyn M, Raifu AO, Massuger LFAG, Bulten J, et al. Cytologic detection of cervical abnormalities using liquid-based compared with conventional cytology: a randomized controlled trial. Obstet Gynecol 2008;112:1327-34.
33. Siebers AG, Klinkhamer PJJM, Grefte JMM, Massuger LFAG, Vedder JEM, Beijers-Broos A, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA 2009;302:1757-64.
34. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009;101:1612-23.
35. Cuzick J, Bergeron C, von Knebel Doeberitz M, Gravitt P, Jeronimo J, Lorincz AT, et al. New technologies and procedures for cervical cancer screening. Vaccine 2012;30 Suppl 5:F107-F116.